Literature review · Tissue recovery / Immune & inflammation

ARA-290

ARA-290 has small exploratory human studies in sarcoidosis-associated small-fibre neuropathy. Some symptom and nerve measurements improved, but these results are not broad evidence of tissue repair or immune benefits.

By HeartPep · Reviewed · 4 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Selected small human studies concern sarcoidosis-associated and diabetic neuropathy. Positive symptom and nerve-related measurements remain exploratory, with developer involvement, multiple outcomes and short observation windows. The 2013 corneal nerve-area measurements have a linked arithmetic correction.

Identity & scope

ARA-290 is the experimental peptide code used in the cited clinical studies. Research on a defined study drug does not verify that a supplier product with the same code is analytically or pharmacologically equivalent.

Catalogue labels covered: ARA-290.

What the research shows

  • The 2012 pilot improved a small-fibre symptom score, while pain and fatigue improved similarly in both groups.
  • The 2013 study reported symptom, corneal-nerve and selected functional changes in patients with documented nerve-fibre loss.

Critical interpretation

Symptoms and nerve images answer different questions

A symptom scale is directly relevant to experience, while corneal imaging can test a proposed biological effect. Concordance would strengthen a hypothesis, but neither measure should be assumed to validate the other. Our interpretation is that selecting a favourable nerve subgroup after seeing the data is less conclusive than prospectively defining that population and reproducing the finding with a prespecified analysis. [2] [3]

Inspect the corrected measurement before pooling

The nerve-area erratum is material to any quantitative synthesis even if a summary does not quote the old numbers. Area, fibre count and fibre density should remain separate variables with their units and algorithms. Before combining studies, a researcher should determine which measurement was corrected and whether the extracted data reflect it, rather than treating every corneal endpoint as interchangeable. [4] [2]

Small studies cannot settle safety

Short trials may suggest feasibility without estimating uncommon or delayed harms. The diabetes report illustrates why abstract-level reassurance should be checked against the full safety section and participant flow. An event judged unrelated does not prove a cause, while an uncertain attribution does not justify ignoring it. Larger independent trials and longer follow-up are needed for a robust benefit-risk assessment. [1] [3]

Limitations & uncertainties

  • Small exploratory trials with several endpoints can overestimate or incompletely characterise effects.
  • Results from sarcoidosis-associated neuropathy cannot establish general nerve regeneration or recovery from unrelated injuries.
  • Study duration and sample size leave important safety and durability questions; catalogue nasal and vial formulations were not validated.

Open research questions

  • Do larger independently replicated trials confirm prespecified benefits?
  • How durable are effects on function, symptoms and objective nerve measures?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (opens in a new tab)

Heij L, Niesters M, Swartjes M, et al. (2012). Molecular Medicine. DOI: 10.2119/molmed.2012.00332 (opens in a new tab) · PMID 23168581

Design & population
Exploratory four-week double-blind placebo-controlled study in 22 sarcoidosis patients with neuropathy symptoms.
What the study found
Small-fibre symptom scores improved more with ARA-290; pain and fatigue scores improved similarly in both groups.
Limits on interpretation
Pilot scale, multiple symptom outcomes and limited duration. The safety observations cannot establish long-term safety.
Human studyNamed compoundAbstract / record checked

2. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (opens in a new tab)

Dahan A, Dunne A, Swartjes M, et al. (2013). Molecular Medicine. DOI: 10.2119/molmed.2013.00122 (opens in a new tab) · PMID 24136731

Design & population
Blinded placebo-controlled study in sarcoidosis-associated small-nerve-fibre loss with short treatment and subsequent follow-up.
What the study found
Reported improved neuropathic symptoms, corneal nerve-fibre density and selected sensory and exercise measurements.
Limits on interpretation
Small disease-specific study with several measures. Nerve-marker changes do not prove general tissue recovery. The corneal nerve-fibre area algorithm was corrected in a 2016 erratum; use corrected values if extracting that endpoint.
Human studyNamed compoundFull text consulted

3. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (opens in a new tab)

Brines M, Dunne AN, van Velzen M, et al. (2015). Molecular Medicine. DOI: 10.2119/molmed.2014.00215 (opens in a new tab) · PMID 25387363

Design & population
Short phase 2 double-blind placebo-controlled study in type 2 diabetes with painful neuropathy; 49 enrolled, 48 analysed. Published online in 2014, PubMed issue record dated 2015.
What the study found
Reported changes in selected glycaemic and neuropathic measures. A corneal-nerve subgroup analysis was post hoc.
Limits on interpretation
Small, short, multiple-outcome study with developer involvement. Serious adverse events occurred, including a withdrawal for renal deterioration; causal attribution was not established.
Technical referenceNamed compoundFull text consulted

4. Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density (opens in a new tab)

Dahan A, Dunne A, Swartjes M, et al. (2016). Molecular Medicine. DOI: 10.2119/molmed.2013.00122.erratum (opens in a new tab) · PMID 28059429

Design & population
Publisher erratum correcting the 2013 corneal nerve-fibre area algorithm, not another participant study.
What the study found
States that the original area values were too small and provides correction and area-normalisation factors.
Limits on interpretation
Do not extract uncorrected absolute nerve-area values from the original paper. Area and nerve-fibre density are distinct measurements.

Search & review scope

Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.

Two early sarcoidosis trials, a short diabetes-neuropathy trial and the corneal nerve-area erratum. Selected full-text methods, endpoints and safety sections consulted where accessible; no comprehensive neuropathy evidence synthesis.

Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.

Recorded search terms
  • 24136731 ARA-290 sarcoidosis small fiber neuropathy
  • "ARA 290 improves symptoms" 2013 Dahan 00122
  • "23168581" ARA "10." Heij
  • ARA 290 type 2 diabetes neuropathy placebo Brines 2015 trial
  • "10.2119/molmed.2013.00122" correction retraction
  • "10.2119/molmed.2014.00215" erratum correction

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. ARA-290: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/ara-290.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes